General Communications. The type of communications described and defined in Article 5.6 herein.
General Communications. The teacher on duty is responsible for communicating all pertinent information regarding, discipline, pupil progress, and other pertinent issues to the other participating teacher on a regular basis.
General Communications. Subject to the Operators’ duty of confidentiality to any third party, the IUK Representative and the National Grid Gas Representative will keep each other informed of all matters which have a significant effect on Natural Gas flow, pressure or quality at the Interconnection Point. Upon an unforeseen change in the Natural Gas flow, pressure or quality, the IUK Representative or the National Grid Gas Representative will inform each other of the nature and estimated extent of the change.
General Communications. Reports, statements, notices and any other communications shall be transmitted to Customer electronically by posting to Customer’s online Account or via e-mail to the e-mail address on Customer’s application, or to such other e-mail address as Customer may from time to time designate to 10TradeFX. Occasionally 10TradeFX may communicate with Customer via postal mail. If Customer does not have access to e-mail, Customer will receive notices and other communications via postal mail. Notices regarding how to electronically review Account statements will be sent to Customers that have no access to e-mail via postal mail. 10TradeFX is not responsible if the correspondence sent by postal mail is not received by Customer or if the postal mail is delayed, regardless of whether the delay or failure to receive the correspondence was caused by 10TradeFX or a third party. All communications sent via postal mail or sent by e-mail shall be deemed transmitted by 10TradeFX when posted or sent and deemed delivered to Customer personally, whether actually received by Customer or not.
General Communications. Partner shall keep Bioprojet reasonably informed as to its progress and activities relating to the Commercialization of the Product for the Partner Territory, including with respect to regulatory matters and meetings with Regulatory Authorities, by way of updates to the JSC at its meetings and as otherwise specified in this Agreement, or as reasonably requested by Bioprojet at any other time. In order to facilitate the Parties’ exercise of their rights and fulfillment of their obligations hereunder, each Party agrees to give due consideration to any comments provided by the other Party with respect to such Commercialization of the Product for the Partner Territory.
General Communications. Each Party shall keep the other Party fully and promptly informed as to its progress and activities relating to the development, commercialization, marketing and promotion of the Product in the Territory, including with respect to regulatory matters and meetings with Regulatory Authorities, by way of updates to appropriate Committees at their meetings and as otherwise specified in this Agreement, or as reasonably requested by the other Party. In connection therewith, XenoPort and GSK shall provide each other with such information regarding such progress and activities under the Development Plan, the Commercialization Plan and/or any Co-Promotion Plan, or otherwise relating to the development of the Product for, or commercialization of the Product in, the Territory, as the other Party may request from time to time. In order to facilitate the Parties’ exercise of their rights and fulfillment of their obligations hereunder, each Party agrees to give due consideration to any comments provided by the other Party with respect to such development, commercialization, marketing and promotion of the Compound and/or any Product for the Territory.
General Communications. Each Party shall keep the other Party fully and promptly informed as to its progress and activities relating to the development, commercialization, marketing and promotion of the Products within the Territory, including with respect to regulatory matters and meetings with Regulatory Authorities, by way of updates to the JSC at their meetings and as otherwise specified in this Agreement, or as reasonably requested by the other Party including providing the other Party promptly with all clinical and regulatory information, filings made prior to the Effective Date and all financial information and data related to its performance under the Agreement to the extent necessary for each Party, on a timely basis, to prepare its internal and external financial reports.
General Communications. Any communication about Philips by Exor and/or its Affiliates, including any filings with the SEC (e.g., Schedule 13D and/or 13G) upon and after obtaining the 15% Threshold Stake, shall be made only after consultation with Philips. Such consultation shall not be required for any communication:
General Communications. Reports, statements, notices, and any other communications shall be transmitted to Customer electronically by posting to Customer’s online Account or via e-mail to the e-mail address on Customer’s application, or to such other e-mail address as Customer may from time to time designate to Evalanch Ltd. Occasionally Evalanch Ltd may communicate with Customer via postal mail. If Customer does not have access to e-mail, Customer will receive notices and other communications via postal mail. Notices regarding how to electronically review Account statements will be sent to Customers that have no access to e-mail via postal mail. Evalanch Ltd is not responsible if the correspondence sent by postal mail is not received by Customer or if the postal mail is delayed, regardless of whether the delay or failure to receive the correspondence was caused by Evalanch Ltd or a third party. All communications sent via postal mail or sent by e-mail shall be deemed transmitted by Evalanch Ltd when posted or sent and deemed delivered to Customer personally, whether actually received by Customer or not.
General Communications. Each Party shall keep the other Party informed, by way of updates to the Joint Steering Committee at its meetings and as otherwise specified in this Agreement, or as reasonably requested by the other Party, as to its progress and activities relating to the Development and Commercialization of the Compound and Products in the Territory, including with respect to regulatory matters and meetings with Regulatory Authorities,. In connection therewith, Amicus and GSK shall provide each other through the Joint Steering Committee with such information regarding such progress and activities under the Development Plan and/or the Marketing Plan, or otherwise relating to the Product, as the other Party may request from time to time.
